Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Janssen Pharmaceutical Discovered First-of-its-Kind ERLEADA® (apalutamide)

The Janssen Pharmaceutical Companies of Johnson & Johnson discovered first-of-its-kind ERLEADA® (apalutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

The androgen receptor inhibitor ERLEADA® (apalutamide) is used to treat non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).

ERLEADA® (apalutamide), is available for patients as the first-and-only next-generation androgen receptor inhibitor with once-daily tablet.  

With two strengths available, the healthcare professionals consists of the flexibility to prescribe 240mg once-daily dose of ERLEADA® either in the form of one 240mg tablet or four 60mg tablets. The patients can prefer single-tablet option to reduce their total number of daily pills.

For patients having difficulty in swallowing tablets, ERLEADA® remains as the only single-tablet androgen receptor inhibitor (ARI) with alternate methods of administration. The 60 mg tablets are approved  for dispersion in applesauce, while the 240 mg tablets are approved for  orange juice, water or applesauce. The 240 mg tablet can also be delivered through a feeding tube.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024